Isolation and Characterisation of Insulin-Releasing Compounds from Pseudechis australis and Pseudechis butleri Venom by Moore, Sara W.M. et al.
 1 
Isolation and characterisation of insulin-releasing compounds from Pseudechis 
australis and Pseudechis butleri venom 
 
 
Sara W.M. Moore, Vikas K. Bhat, Peter R. Flatt, Victor A. Gault and Stephen McClean 
 
SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, University of 
Ulster, Coleraine, Northern Ireland, UK 
 
 
 
Corresponding author: Dr Stephen McClean, The SAAD Centre for Pharmacy and Diabetes, 
School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, 
UK. Tel.: +44(28)7012 4406; E-mail: s.mcclean@ulster.ac.uk 
 
 2 
Abstract 
 
Crude venom from two elapid snakes Pseudechis australis and Pseudechis butleri was 
fractionated by gel filtration chromatography and selected fractions screened for in vitro 
insulin-releasing activity using clonal pancreatic BRIN-BD11 cells. Following acute 20-min 
incubation at 5.6 mM glucose, 9 fractions exhibited significant (P < 0.001) insulin-releasing 
activity. Structural characterisation of active fractions was achieved primarily using MALDI–
TOF MS and N-terminal Edman degradation sequencing. The partial N-terminal sequences 
are reported for a total of 7 venom components. Their homology to existing sequences as 
determined using BLAST searching uncovered the main insulin-releasing families as being 
phospholipases A2 and short α-neurotoxins. A number of sequences are reported for the first 
time from Pseudechis butleri venom which is much less studied than the related Pseudechis 
australis.  
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1.0 Introduction 
Reptiles and their venom products have been used traditionally for many years in the 
treatment of human disease and ailments. Snake fat has been used as both an anti-rheumatic 
ointment and as relief for sore throats whilst dried snake skin has been claimed to act as a 
cough suppressant, a diuretic for kidney stones and to have anti-rhinitic properties (Quave et 
al. 2010). Snake meat is classed as a medicinal food; fried and eaten to purify the blood, with 
leftover cooking used oil as an anti-scabies treatment, or being applied to disinfect and heal 
wounds (Quave et al. 2010). The composition of snake venom components has been 
 3 
extensively reviewed (Tu, 1996). Several factors have been shown to be influential in 
determining composition of snake venom through differences at the genus level (Vonk et al. 
2011).  They contain a mixture of both enzymatic and non-enzymatic proteins (Walker et al. 
2013).  As reviewed by Escoubas and colleagues (2008), the main structural families present 
in snake venom include serine proteinases, CRISP (cysteine-rich secretory proteins), L-amino 
acid oxidases, C-type lectin-like proteins, disintegrins, metalloproteinases and phospholipases 
A2. 
 
Recent figures estimate that expenditure for diabetes care and associated complications 
generate a considerable social and economic burden (Seuring et al. 2015). The quest for new 
biomolecules that may be useful for diabetes therapy has opened up the exploration of natural 
products and in particular animal venoms. Indeed, the best known example of a venom-
derived treatment for type 2 diabetes is the incretin mimetic exendin-4 (Byetta) which was 
isolated from the Gila monster Heloderma suspectum (King 2011). Exendin-4 is a 39-amino 
acid peptide which has a 53% sequence identity to glucagon-like peptide-1 (GLP-1) and 
displays bioactivities similar to GLP-1 but with a protracted biological half-life (Lund et al. 
2014). 
 
There are several examples of snake venom constituents and crude snake venom suggestive 
of insulin-releasing properties. A decrease in glucose concentrations was detected following 
injection of crude venom from Crotalus durissus terrificus rattlesnake (Hernández Cruz et al. 
2008). Cardiotoxin (CTX-1), a peptide isolated from the venom of the Naja kaouthia snake, 
has been described by Nguyen and co-workers (2012) as a potent insulin secretagogue when 
tested in INS-1E cells with no cytotoxicity. Various Crotalus species have also been 
examined, with a dose-dependent increase in insulin secretion reported by Toyama and 
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colleagues (2005) for the crotamine isoform Cro 2 from the Crotalus durissus cascavella. 
Indeed, research from our laboratory has shown that venom from the vipers Crotalus 
adamanteus, Crotalus vegrandis and Bitis nasicornis contain insulin-releasing compounds 
such as serine proteinases, phospholipases A2 (PLA2) and disintegrins (Moore et al. 2015). 
Supported by our previous work and existing literature on the ability of various snake venom 
components to stimulate insulin-release, two Elapidae snakes, Pseudechis butleri and 
Pseudechis australis, were chosen for study. A number of venom chromatographic fractions, 
corresponding to phospholipase A2 and -neurotoxins, exhibited a significant elevation in 
insulin-release when examined in BRIN-BD11 pancreatic beta-cells.  
 
 
2.0 Materials and methods 
2.1 Materials 
Pseudechis australis and Pseudechis butleri venoms were obtained from Venom Supplies, 
Pty Ltd. (Tanunda, South Australia). HPLC-grade water (VWR International, 
Geldenaaksebaan, Leuven, Belgium) and ammonium acetate (Fisher Scientific, UK) were 
used to prepare LC mobile phase. RPMI-1640 tissue culture medium, foetal calf serum, 
penicillin and streptomycin were obtained from Gibco (Paisley, Strathcylde, UK). Sinapinic 
acid and α-cyano-4-hydroxycinnamic acid (CHCA) were obtained from Fluka, Sigma-
Aldrich, (Dorset UK) and used as matrices for MALDI-TOF MS analysis. Reagents for N-
terminal Edman degradation sequencing were obtained from Perkin-Elmer Biosystems 
(Warrington, UK). All other chemicals were of analytical grade or better.   
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2.2 Crude venom fractionation  
Crude snake venom was fractioned by gel filtration chromatography on a Spectra System 
HPLC (Thermo Separation Products, Riviera Beach, FL, USA) using Superdex 75 10/300 GL 
column (10 x 300 mm GE Healthcare Life Sciences, Buckinghamshire, UK). Venoms (15 
mg/mL in 0.1 M ammonium acetate) were centrifuged (10,000 rpm for 5 min) and 
supernatant (200 L) chromatographed at ambient temperature using isocratic mobile phase 
(100% 0.1 M ammonium acetate) at flow rate of 0.7 mL/min. LC effluent was monitored at 
214 and 280 nm and fractions collected every min using automatic fraction collector 
(Pharmacia LKB Frac-100, Uppsala, Sweden) over 90-min run time and fractions capped and 
stored at 4oC prior to further analysis. 
 
2.3 MALDI-TOF MS and N-terminal Edman degradation sequencing 
Guided by LC-UV response for each venom fractionation, individual test fractions were 
analysed using PerSeptive Biosystems Voyager-DE Biospectrometer MALDI-TOF mass 
spectrometer. Internal mass calibration instrument was performed prior to sample analysis 
using Peptide Calibration Mix 2 as described previously (Moore et al. 2015). Test sample 
(1.5 L) was pipetted onto one pre-defined well of a 100-well stainless steel plate and 
allowed to dry at room temperature. A 10 mg/mL solution of appropriate matrix (CHCA or 
sinapinic acid) was prepared in 50% acetonitrile: 50% HPLC water with 0.1% TFA. The 
plate was inserted into the MALDI-TOF and all measurements collected in linear positive 
ionisation mode using minimum of 50 laser shots. For CHCA matrix, accelerating voltage 
was maintained at 20,000 V with grid voltage and guide wire voltages set at 94% and 0.05%, 
respectively. For sinapinic acid matrix, accelerating voltage was changed to 25,000 V and 
grid voltage and guide wire voltage set to 92% and 0.3%, respectively. Nitrogen laser (337 
nm) was directed toward the densest area of the sample/matrix spot, the laser intensity 
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adjusted to obtain optimal spectral response and mass/charge ratio plotted against relative 
abundance. For Edman sequencing, sample was immobilised onto BioBrene Plus filter 
(Applied Biosystems) and partial amino acid sequence of a number of fractions performed 
using Perkin Elmer Applied Biosystems 491 Protein Sequencer using standard protocols 
(Moore et al. 2015).  
 
2.4 In vitro insulin release studies 
Test fractions for acute insulin-release assay were selected based primarily on MALDI-TOF 
MS results. An aliquot of each LC fraction (500 L) and blank (500 L 0.1 M ammonium 
acetate) were placed in the freezer overnight at -70C overnight and subsequently freeze-
dried using Heto PowerDry PL6000 freeze drier (Thermo Electron Corporation, Waltham, 
MA, USA). BRIN-BD11 cells (see McClenaghan et al. 1996 for origin and characteristics of 
BRIN-BD11 cells) were cultured in sterile tissue culture flasks (Orange Scientific, Braine-l’ 
Alleud, Belgium) using RPMI-1640 tissue culture medium containing 11.1 mM glucose, 10% 
v/v foetal calf serum, and 1% (v/v) antibiotics (100 U/mL penicillin, 0.1 mg/mL 
streptomycin). Cells were incubated in a LEEC incubator (LEEC, Nottingham, UK) at 37C 
in atmosphere of 5% CO2. For acute insulin-release studies BRIN-BD11 cells were seeded 
into 24-well plates and experiments performed as described previously (Moore et al. 2015). 
Samples for testing (500 L) were reconstituted and insulin-release performed at 37C for 20 
min using Krebs Ringer Bicarbonate Buffer (KRBB) supplemented with 5.6 mM glucose 
(500 L). We chose to test selected compounds from snake venom at 5.6 mM glucose as this 
represents a physiological non-stimulatory concentration to test for novel insulinotropic 
activity (McClenaghan et al. 1996). Following incubation, insulin released into the 
supernatant was determined by radioimmunoassay (Flatt and Bailey, 1981). Basal 
(unstimulated) levels of insulin release were set to 100% (control).  
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2.5 Statistical Analysis 
Insulin-release data are expressed as mean ± SEM and results analysed using Student’s 
unpaired t-test. P < 0.05 was deemed to be statistically significant.  
 
3.0 Results 
3.1 Crude venom fractionation  
Figures 1a and 1b illustrate the UV profile for Pseudechis australis and Pseudechis butleri, 
respectively. Chromatograms for both Pseudechis species are identical with exception of one 
additional peak with Pseudechis butleri eluting at 21.11 min on the shoulder of the main peak 
at approximately 19 min. In line with the principles of size-exclusion chromatography, 
MALDI-TOF data for the individual venom fractions generally indicates a decrease in 
molecular weight of eluted components with increasing retention time. No further 
purification was performed on any of the LC fractions and consequently the individual 
fractions are likely to contain more than one component. MALDI-TOF MS analysis was 
performed on all of the fractions tested for insulin-release using both CHCA and sinapinic 
acid matrices. Further characterisation of the fractions comprised a review of the 
experimental MALDI-TOF masses with those deposited in the Uniprot database and N-
terminal degradation sequencing of suitable fractions.   
 
3.2 Pseudechis australis in vitro insulin-release and structural characterisation 
Four Pseudechis australis fractions were selected for insulin-release testing and all exhibited 
significant insulin-releasing activity (1.6 to 1.9-fold; P<0.001) compared to 5.6 mM glucose 
alone (Figure 2). MALDI-TOF mass spectrum for Pseudechis australis fraction 17 collected 
with sinapinic acid matrix showed singly charged species as the base peak at m/z 27704.21 
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with the doubly charged species also evident at m/z 13854.33. Closer inspection also revealed 
a further two peaks of lower intensity at m/z 27555.01 and m/z 27859.60 either side of the 
base peak. When subjected to N-terminal degradation sequencing the first 30 residues was 
determined as: NLYQFYEMIECANFGTISGLAYAGYYCYCG. A BLAST search indicated 
this sequence to have 90% homology with residues 28 to 57 of the phospholipase A2 enzyme 
Pseudechis cf. australis HI-2009 (GenBank: BAJ07178.1; Table 1). 
 
Edman degradation sequencing for fraction 19 indicated similarity to phospholipase A2 
family. With at least three main components of masses of approximately 13 kDa, partial 
Edman sequence determined NLIQFGWMIQCANKGSRPSLDYADYGCYCGWG forms a 
core stretch in each of these. As shown in Table 1 this experimental sequence shares a 97% 
homology with each of the following: phospholipase A2 enzyme Pseudechis cf. australis HI-
2009 (GenBank: BAJ07180.1); Pa-11 precursor from the Pseudechis australis (GenBank: 
AAZ22660.1); basic phospholipase A2 PA-11 (UniProtKB/Swiss-Prot: P04056.1); and basic 
phospholipase A2 PA-12C (UniProtKB/Swiss-Prot: P20256.1).  
 
MALDI-TOF spectrum for fraction 21 showed two main peaks at m/z 13191.41 and m/z 
13114.77 with the former peak also present in fraction 22 at approximately 82% intensity. 
Based solely on observed experimental masses, these are most probably PLA2 type 
compounds. The base peak in fraction 22 with m/z 6711.52 is not comparable to any of the 
UniProt masses listed for Pseudechis australis. However, a similar sized peak of m/z 6745.08 
discussed later with the results for Pseudechis butleri fraction 22 was found to belong to the 
snake three-finger toxin family. Further sequencing would be required to confirm if this is 
indeed the correct family assignment. Structural characterisation by Edman was not 
attempted as the fraction contained a mixture of peptides.  
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3.3 Pseudechis butleri in vitro insulin-release and structural characterisation 
A significantly elevated insulin-release (1.3 to 2.3-fold; P<0.001) was observed for 
Pseudechis butleri test fractions 14, 18, 19, 21 and 22 (Figure 2). Fraction 14 coincided with 
the first peak eluted peak on the UV profile for the Pseudechis butleri fractionation, but the 
complexity and presence of high molecular weight components at ~23.5 kDa and 53 kDa 
restricted further structural characterisation. These masses were not comparable with any of 
the masses published in UniProt database for Pseudechis butleri. Although complex with two 
main peaks at m/z 13085.87 and 13246.16, fraction 18 was subjected to N-terminal 
degradation sequencing with a partial sequence established. The first sequence was 
determined as: NLIQFGNMIQCANKGQYPELAYADY which shares 84% homology with 
residues 1 to 25 of the basic phospholipases A2 PA-11 (UniProtKB/Swiss-Prot: P04056.1), 
PA-12C (UniProtKB/Swiss-Prot: P20256.1) and PA-12A (UniProtKB/Swiss-Prot: 
P20255.1). Furthermore, it also shares 84% homology with residues 28 to 52 of the Pa-11 
precursor Pseudechis australis (GenBank: AAZ22660.1) and phospholipase A2 enzyme 
Pseudechis cf. australis HI-2009 (GenBank: BAJ07180.1). The mass of this second 
component at ca. 13 kDa would imply that it belongs to the PLA2 family, yet as shown in 
Table 2, a BLAST search restricted to the Pseudechis species shows only a 69% homology 
with residues 28 to 43 of the phospholipase A2 enzyme Pseudechis cf. australis HI-2009 
(GenBank: BAJ07178.1). Widening the search parameters indicated 56% homology to a 
PLA2 protein from the Indian elapid Bungaris fasciatus. Further purification for this fraction 
would be required to allow the second component to be sequenced on its own.  
 
The MALDI-TOF spectra of fractions 19 and 21 showed some commonality with a main 
cluster of peaks present at approximately 13 kDa. Although both fractions 19 and 21 
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promoted significant insulin-release (P<0.001), fraction 21 elicited greater insulin-release 
which has a notable peak of m/z 6733.41 at 70% intensity. Fraction 19 was not sequenced but 
the partial sequences for two components of fraction 21 were established by Edman 
degradation sequencing. As shown in Table 2, a BLAST search of the first sequence 
NILQFRKMIQCANKGSRAAWHYLDYG showed 100% homology with the N-terminal 
sequences deposited for the basic phospholipases A2 PA-13 (UniProtKB/Swiss-Prot: 
P04057.1) and PA-15 (UniProtKB/Swiss-Prot: P20257.1) from Pseudechis australis. It also 
showed 100% homology with residues 28 to 53 of both the Pseudechis australis Pa-13 
precursor (GenBank: AAZ22665.1) and phospholipase A2 enzyme Pseudechis cf. australis 
HI-2009 (GenBank: BAJ07181.1). The second sequence identified for fraction 21 was: 
NTCENCTSSEPLTITKCCGGDSSCCKC. Results of the BLAST search indicate a shared 
homology of 56% with short neurotoxin 1 from Pseudechis porphyriacus (UniProtKB/Swiss-
Prot: A8HDJ4.1) and 58% homology with another short neurotoxin 1 from Naja mossambica 
(UniProtKB/Swiss-Prot: P01431.1). It had been assumed that the two sequences for fraction 
21 would have corresponded to the two most intense peaks at m/z 13185.43 and m/z 
13111.23 and both been PLA2 type compounds. However, results for the Edman sequencing 
indicate one PLA2 and one short neurotoxin. This would suggest that the residues sequenced 
for PLA2 are core to both of the main peaks at ~13 kDa with the sequence for the short 
neurotoxin corresponding to the peak of m/z 6733.41 at 70% intensity.  
 
For Pseudechis butleri fraction 22, the small peak detected on the UV profile eluting on the 
shoulder of the main peak at 21.11 min is manifest as the base peak at m/z 6745.08 on the 
MALDI-TOF MS spectrum.  Similar to fraction 21, the presence of a PLA2 type compound 
of ~13 kDa and a lower mass compound of ~6.7 kDa in fraction 22 appears to have a positive 
influence on promoting insulin-release. The following sequence information was obtained for 
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Pseudechis butleri fraction 22 when subjected to Edman degradation sequencing: 
MTCANQQSIQPKTTTINAGGESSCYKKTW (Table 2). This sequence shows 90% 
homology with the 83 amino acid short neurotoxin 1 isolated from Pseudechis australis 
(UniProtKB/Swiss-Prot: P25497.2) which belongs to the snake three-finger toxin family.  
 
 
4.0 Discussion 
The insulin-releasing activity of snake venom components fractionated from Pseudechis 
australis and Pseudechis butleri crude venoms was examined using clonal BRIN-BD11 beta-
cells. Due to the relatively higher mass range of snake venom constituents, gel filtration 
chromatography is frequently used for their fractionation (Graham et al. 2008; Blacklow et 
al. 2010). From UV elution profiles presented for each of the snake venoms there is a 
comparable profile for the two Pseudechis venoms investigated. Despite differing run 
conditions there is also similarly between chromatograms presented in this study and a size-
exclusion profile for the related species Pseudechis papuanus as reported by Graham and 
colleagues (2008). These authors claimed that size-exclusion chromatography offered a 
robust means of correctly classifying a snake as belonging to either the viper or elapid 
families based on the observed profile and our findings corroborate this. Nine fractions were 
found to exhibit significantly elevated insulinotropic activity. Structural characterisation of 
the active fractions either by Edman degradation sequencing or by comparison of the 
experimental MALDI-TOF derived masses with published masses revealed snake toxins of 
varying molecular weight, from a range of different toxin families. In fact, this study is the 
first to report the presence of PLA2 and short neurotoxin proteins in the lesser-studied 
Pseudechis butleri venom. 
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The phospholipase A2 (PLA2 EC 3.1.1.4 phosphatidylcholine 2-acylhydrolyase) family of 
snake toxins predominate the fractionations of Pseudechis australis and Pseudechis butleri 
venom. All of the venom test fractions showing evidence of PLA2 type compounds exhibit a 
significant insulin-releasing activity. This finding is in keeping with previous work on elapid 
venom, in particular from Naja mossambica mossambica (Juhl et al. 2003) and Micropechis 
ikaheka (Gao et al. 2001) which contain insulinotropic PLA2 proteins. Venom from Crotalus 
vipers has also been studied where the presence of PLA2 compounds had a significant effect 
on insulin secretion (Moore et al. 2015; Yamamoto et al. 1983; Nogueira et al. 2005). The 
mechanism behind the insulinotropic activity of phospholipase molecules is thought to 
involve hydrolysis of membrane phospholipids initiating release of arachidonic acid. This is 
converted to lipoxygenase products which in turn results in elevated cytosolic Ca2+ and 
insulin secretion (Persaud et al. 2007).  
 
Takasaki and colleagues (1990) reported the amino acid sequences of eight phospholipases 
isolated from Pseudechis australis and define the following hydrophilic residues Arg-43, 
Lys-46, Asp-50, Glu-54, Lys-58, Asp-90 and Glu-94 as being responsible for presynaptic 
toxicity. For those sequenced PLA2s in Pseudechis butleri fraction 18 and Pseudechis 
australis fraction 19 which show homology with Pa-11, a phospholipase A2 that is reported 
by Nishida and co-workers (1985) as being toxic, there is a possibility of non-specific toxic 
effects on beta-cells in this study. Following the same line of reasoning, Pseudechis butleri 
fraction 21 was shown to be comparable to the non-toxic Pa-13 and therefore might be 
expected to be free from adverse effects (Nishida et al 1985). However, further studies using 
pure preparations are required to elucidate exact molecular mechanisms of action together 
with potential toxic effects.   
 
 13 
As reviewed by Barber and co-workers (2013), snake venom α-neurotoxins are known as 
postsynaptic neurotoxins which bind to the skeletal nicotinic acetylcholine receptor and block 
neuromuscular transmission. With ability to cause paralysis, their presence in snake venom is 
key to efficient prey acquisition. Short chain α-neurotoxins belonging to the three-finger 
toxin family were identified in the elapid snake venoms of this study. On the three occasions 
where short α-neurotoxins were either inferred from the MALDI-TOF mass (Pseudechis 
australis fraction 22) or confirmed through Edman sequencing (Pseudechis butleri fractions 
21 and 22), there is also evidence of PLA2 type compounds co-eluting in the same fraction. 
Each of these fractions enhanced insulin-release, but given the known insulin releasing 
properties of phospholipases A2, it is difficult to assess the individual contribution of the short 
α-neurotoxins to insulinotropic activity. As mentioned previously there was also a PLA2 
entity present in this fraction which was deemed to be comparable to the non-toxic Pa-13.  
 
The current study and previous work from our group (Moore et al. 2015) have identified the 
potential of elapid and viper venoms as a source of molecules with insulin-releasing 
properties. Although further detailed studies are required to evaluate any possible therapeutic 
ability, the small scale proteomic analysis of the individual snake venoms examined in this 
research, combined with biological activity testing has made a significant contribution to the 
rapidly emerging field of venomics.  
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Tables and Figures 
Table 1 Edman degradation sequencing results for Pseudechis australis fractions aligned against homologous sequences identified using BLAST 
searching. 
 
 
Sequence (Residue numbers in bold text) Homology Database matches 
17  1  NLYQFYEMIECANFGTISGLAYAGYYCYCG        30   N/A Determined by N-terminal Edman degradation sequencing 
 28  NLYQFKEMIECANKGTISGLAYAGYGCYCG        57 90% 
Phospholipase A2 enzyme [Pseudechis cf. australis HI-2009] 
(GenBank: BAJ07178.1) 
19  1  NLIQFGWMIQCANKGSRPSLDYADYGCYCGWG      32 N/A Determined by N-terminal Edman degradation sequencing 
 28  NLIQFGNMIQCANKGSRPSLDYADYGCYCGWG      59 97% 
Phospholipase A2 enzyme Pseudechis cf. australis HI-2009 (GenBank: 
BAJ07180.1); 
 28  NLIQFGNMIQCANKGSRPSLDYADYGCYCGWG      59 97% Pa-11 precursor from the Pseudechis australis (GenBank: AAZ22660.1); 
  1  NLIQFGNMIQCANKGSRPSLDYADYGCYCGWG      32 97% 
Basic phospholipase A2 PA-11 Pseudechis australis (UniProtKB/Swiss-
Prot: P04056.1) 
  1  NLIQFGNMIQCANKGSRPSLDYADYGCYCGWG      32 97% 
Basic phospholipase A2 PA-12C Pseudechis australis (UniProtKB/Swiss-
Prot: P20256.1), 
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Table 2 Edman degradation sequencing results for Pseudechis butleri fractions aligned against homologous sequences identified using the BLAST 
search. 
 Sequence (Residue numbers in bold text) Homology Database matches 
18  1  NLIQFGNMIQCANKGQYPELAYADY             25   N/A Determined by N-terminal Edman degradation sequencing 
  1  NLIQFGNMIQCANKGSRPSLDYADY             25 84% 
Basic phospholipase A2 PA-11 Pseudechis australis (UniProtKB/Swiss-
Prot: P04056.1) 
  1  NLIQFGNMIQCANKGSRPSLDYADY             25 84% 
Basic phospholipase A2 PA-12C Pseudechis australis (UniProtKB/Swiss-
Prot: P20256.1) 
  1  NLIQFGNMIQCANKGSRPSLNYADY             25 84% 
Basic phospholipase A2 PA-12A Pseudechis australis (UniProtKB/Swiss-
Prot: P20255.1) 
 28  NLIQFGNMIQCANKGSRPSLDYADY             52 84% Pa-11 precursor Pseudechis australis (GenBank: AAZ22660.1) 
 28  NLIQFGNMIQCANKGSRPSLDYADY             52 84% 
Phospholipase A2 enzyme Pseudechis cf. australis HI-2009 (GenBank: 
BAJ07180.1) 
  1  DLYEFLEMIECAAKVTFPLRDYLTY             25 N/A Determined by N-terminal Edman degradation sequencing 
 28  NLYQFKEMIECANKGT                      43 69% 
Phospholipase A2 enzyme Pseudechis cf. australis HI-2009 (GenBank: 
BAJ07178.1) 
 18  DLLQFNEMIECTIPGSFPLLDYMDY             42 56% 
Acidic phospholipase A2 KBf-grIB Bungarus fasciatus (Genbank: 
DQ508411.1) 
21  1  NILQFRKMIQCANKGSRAAWHYLDYG            26 N/A Determined by N-terminal Edman degradation sequencing 
  1  NILQFRKMIQCANKGSRAAWHYLDYG            26 100% 
Basic phospholipase A2 PA-13 Pseudechis australis (UniProtKB/Swiss-
Prot: P04057.1) 
  1  NILQFRKMIQCANKGSRAAWHYLDYG            26 100% 
Basic phospholipase A2 PA-15 Pseudechis australis (UniProtKB/Swiss-
Prot: P20257.1) 
 28  NILQFRKMIQCANKGSRAAWHYLDYG            53 100% Pa-13 precursor Pseudechis australis (GenBank: AAZ22665.1) 
 28  NILQFRKMIQCANKGSRAAWHYLDYG            53 100% 
Phospholipase A2 enzyme Pseudechis cf. australis HI-2009 (GenBank: 
BAJ07181.1) 
  1  NTCENCT  SSEPLTITKCCGGDSSCCKC         27 N/A Determined by N-terminal Edman degradation sequencing 
 
23   TC--CNQQSSQPKTTTTCAGGESSCYK          47 56% 
Short neurotoxin 1 Pseudechis porphyriacus (UniProtKB/Swiss-Prot: 
A8HDJ4.1) 
 8           SSEPPTTTRCSGGETNCYK          26 58% Short neurotoxin 1 Naja mossambica (UniProtKB/Swiss-Prot: P01431.1) 
22  1  MTCANQQSIQPKTTTINAGGESSCYKKTW         29   N/A Determined by N-terminal Edman degradation sequencing 
 22  MTCCNQQSSQPKTTTICAGGESSCYKKTW         50   90% 
Short neurotoxin 1 Pseudechis australis(UniProtKB/Swiss-Prot: 
P25497.2) 
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Figure 1 HPLC fractionation of (a) Pseudechis australis and (b) Pseudechis butleri 
crude venom using a Superdex 75 10/300 GL column (10 x 300 mm) and an isocratic 
mobile phase of 0.1 M ammonium acetate at 0.7 mL/min over 90 min with UV 
detection at 280 nm. 
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Figure 2 Effects of selected HPLC fractions of Pseudechis australis and Pseudechis 
butleri crude venom on insulin secretion from BRIN-BD11 cells in the presence of 5.6 
mM glucose. Values represent means  SEM. ***P<0.001 compared with 5.6 mM 
glucose control (n=5). 
 
 
 
 
